Annexon
Watchlist
Annexon
Blockbuster Potential in Ophthalmology and Insider Purchases!
With Vonaprument, the rapidly growing market for ophthalmology is being addressed. If FDA approval occurs at the end of 2026 or early 2027, long-term blockbuster potential could arise!
Reading Time: 1 minute
Speculative biotechnology companies are currently in the spotlight of investors due to progress in studies, positive analyst comments, M&A fantasies, and insider purchases. In this context, Annexon Inc. (ANNX) (i.) can also present a positive outlook. The biotech company is pursuing an interesting approach, focusing on the development of complement system inhibitors, specifically targeting the starting molecule C1q. The complement system is part of the immune system. Normally, it helps to destroy pathogens. However, in many autoimmune and neurodegenerative...
Read this article now with a free account.
Your benefits:
- Every month, you can read 5 articles from the premium section for free.
- Monthly 2 trial issues of the Trader newspaper for free.
- Create a personal watchlist with an overview of news about your stock.
